1-20 of 25
Michael Untch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P4-11-12: CLEAR-B - Adjuvant therapy effectiveness in patients with primary breast cancer: A retrospective registry study

Free
Bahriye Aktas, Hanna Huebner, Andreas Hartkopf, Maggie Banys-Paluchowski, Ingolf Juhasz-Böss, Nadia Harbeck, Hans-Christian Kolberg, Elmar Stickeler, Marcus Schmidt, Marc Thill, Michael Untch, Thorsten Kühn, Nina Ditsch, Lothar Häberle, Manuel Hoerner, Daniel Anetsberger, Kathrin Nicole Truch, Christian Roos, Christian Mann, Erik Belleville, Tanja Fehm, Peter A. Fasching
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P4-11-12.
https://doi.org/10.1158/1557-3265.SABCS24-P4-11-12
Published: 13 June 2025
View articletitled, Abstract P4-11-12: CLEAR-B - Adjuvant therapy effectiveness in patients with primary breast cancer: A retrospective registry study
Journal Articles

Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC

Free
Joyce O’Shaughnessy, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Razvan Cristescu, Andrey Loboda, Petar Jelinic, Lingkang Huang, Kim Kraynyak, Wilbur Pan, Jaime Mejia, Peter Schmid
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): LB1-07.
https://doi.org/10.1158/1557-3265.SABCS24-LB1-07
Published: 13 June 2025
View articletitled, Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC
Journal Articles

Abstract P1-04-29: The expression patterns of the immune checkpoint molecules PD-1 and PD-L1 in the context of seroma development in breast cancer

Free
Nina Ditsch, Nicole Pochert, Felicitas Schneider, Fritzi Schittek, Melitta Köpke, Udo Jeschke, Mariella Schneider, Aline Metz, Matthias Reiger, Claudia Traidl-Hoffmann, Christian Dannecker, Carl Mathis Wild, Ludwig Christian Hinske, Johanna Veh, Natalie Rohrmoser, Eva Leopoldsberger, Laura Bähner, Steffi Hartmann, Michael Untch, Maggie Banys-Paluchowski, Thorsten Kühn, Nina Ditsch
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-04-29.
https://doi.org/10.1158/1557-3265.SABCS24-P1-04-29
Published: 13 June 2025
View articletitled, Abstract P1-04-29: The expression patterns of the immune checkpoint molecules PD-1 and PD-L1 in the context of seroma development in breast cancer
Journal Articles

Abstract RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies

Free
Johannes Holtschmidt, Fabienne Warnecke, Andreas Schneeweiss, Peter A. Fasching, Theresa Link, Sabine Schmatloch, Mattea Reinisch, Peter Klare, Carsten Denkert, Marianne Just, Vesna Bjelic-Radisic, Claus Hanusch, Jens-Uwe Blohmer, Michael Untch, Christoph Salat, Kristina Lübbe, Jens Huober, Kerstin Rhiem, Valentina Nekljudova, Sibylle Loibl, Christine Solbach
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): RF2-02.
https://doi.org/10.1158/1557-3265.SABCS24-RF2-02
Published: 13 June 2025
View articletitled, Abstract RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies
Journal Articles

Abstract P3-10-29: Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387) - On the way to identify women at risk of developing seroma after mastectomy

Free
Nina Ditsch, Melitta Koepke, Nicole Pochert, Udo Jeschke, Mariella Schneider, Matthias Reiger, Claudia Traidl-Hoffmann, Angelika Mattmer, Shirin Hunstiger, Jacqueline Sagasser, Christian Dannecker, Mathis Wild, Christian Hinske, Sarah Friedrich, Steffi Hartmann, Henning Kahl, David Krug, Natalia Krawczyk, Kerstin Stemmer, Regina Fluhrer, Andreas Raue, Maria Luisa Gasparri, Roland Reitsamer, Justyna Jelinska, Güldeniz Cakmak, Eduard Bonci, Rachel Wuerstlein, Visnja Fink, Vesna Bjelic-Radisic, Marc Thill, Christoph Heitmann, Walter Weber, Annette Lebeau, Hans-Christian Kolberg, Toralf Reimer, Rosa di Micco, Jana de Boniface, Oreste Gentillini, Michael Untch, Maggie Banys-Paluchowski, Thorsten Kuehn
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-10-29.
https://doi.org/10.1158/1557-3265.SABCS24-P3-10-29
Published: 13 June 2025
View articletitled, Abstract P3-10-29: Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387) - On the way to identify women at risk of developing seroma after mastectomy
Journal Articles

Abstract P3-10-22: Preoperative radiotherapy versus postoperative radiotherapy after neoadjuvant chemotherapy in high-risk breast cancer: a prospective, randomized, international multicentre Phase III trial—NeoRad

Free
Christiane Matuschek, Tanja Fehm, Maria Hufnagel, Vesna Bjelic-Radisic, Michael Untch, Michael Golatta, Danny Jazmati, Thorsten Kühn, David Krug, Jens Blohmer, Carsten Denkert, Beyhan Ataseven, Carolin Nestle-Krämling, Stefanie Corradini, Jens Huober, Jens Huober, Eugen Ruckhaeberle, Andreas Hartkopf, Theresa Link, Kerstin Rhiem, Elmar Stickeler, Claus Hanusch, Jörg Heil, Christine Solbach, Mattea Reinisch, Inga Bekes, Johannes Holtschmidt, Valentina Nekljudova, Sibylle Loibl, Wilfried Budach
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-10-22.
https://doi.org/10.1158/1557-3265.SABCS24-P3-10-22
Published: 13 June 2025
View articletitled, Abstract P3-10-22: Preoperative radiotherapy versus postoperative radiotherapy after neoadjuvant chemotherapy in high-risk breast cancer: a prospective, randomized, international multicentre Phase III trial—NeoRad
Journal Articles

Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study

Available to Purchase
Peter A. Fasching, Sabine Schmatloch, Jan Hauke, Julia Rey, Christian Jackisch, Peter Klare, Theresa Link, Claus Hanusch, Jens Huober, Andrea Stefek, Johannes Holtschmidt, Andreas Schneeweiss, Christoph Uleer, Wolfgang D. Schmitt, Gabriele Doering, Kerstin Rhiem, Carsten Denkert, Rita K. Schmutzler, Christine Solbach, Eric Hahnen, Andreas Hartkopf, Michael Untch, Vesna Bjelic-Radisic, Valentina Nekljudova, Jens-Uwe Blohmer, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (9): 1596–1604.
https://doi.org/10.1158/1078-0432.CCR-24-2806
Published: 01 May 2025
View articletitled, Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Open the PDF for Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study in another window
Includes: Supplementary data
Journal Articles

Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

Open Access
Peter A. Fasching, Dennis Slamon, Zbigniew Nowecki, Bozena Kukielka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun-Sheng Huang, Arlene Chan, Stephen Chia, Miguel Martín, Hope S. Rugo, Sherene Loi, Sara Hurvitz, Michael Untch, Karen Afenjar, Rodrigo Fresco, Andriy Danyliv, Ilia Ferrusi, Zheng Li, Gabriel Hortobagyi
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (9): 1625–1635.
https://doi.org/10.1158/1078-0432.CCR-24-1724
Published: 01 May 2025
View articletitled, Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Open the PDF for Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial in another window
Includes: Supplementary data
Journal Articles

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials

Available to Purchase
Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, Knut Engels, Christine Solbach, Kurt Diebold, Frederik Marmé, Volkmar Müller, Andreas Schneeweiss, Hans-Peter Sinn, Tanja Fehm, Christian Schem, Elmar Stickeler, Peter Fasching, Jan Budczies, Bärbel Felder, Valentina Nekljudova, Johannes Holtschmidt, Michael Untch, Carsten Denkert, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3868–3880.
https://doi.org/10.1158/1078-0432.CCR-24-0459
Published: 03 September 2024
View articletitled, An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Open the PDF for An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials in another window
Includes: Supplementary data
Journal Articles

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

Available to Purchase
Theresa Link, Jens-Uwe Blohmer, Wolfgang D. Schmitt, Jan Dominik Kuhlmann, Marianne Just, Michael Untch, Oliver Stotzer, Peter A. Fasching, Marc Thill, Mattea Reinisch, Andreas Schneeweiss, Pauline Wimberger, Sabine Seiler, Jens Huober, Christian Jackisch, Kerstin Rhiem, Claus Hanusch, Bruno V. Sinn, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4606–4612.
https://doi.org/10.1158/1078-0432.CCR-23-1801
Published: 14 November 2023
View articletitled, RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Open the PDF for RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial in another window
Includes: Supplementary data
Journal Articles

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial

Available to Purchase
Terence M. Williams, Andreas Schneeweiss, Christian Jackisch, Changxian Shen, Karsten E. Weber, Peter A. Fasching, Carsten Denkert, Jenny Furlanetto, Ernst Heinmöller, Sabine Schmatloch, Thomas Karn, Christopher W. Szeto, Marion T. van Mackelenbergh, Valentina Nekljudova, Elmar Stickeler, Patrick Soon-Shiong, Christian Schem, Thomas Mairinger, Volkmar Müller, Frederik Marme, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3384–3394.
https://doi.org/10.1158/1078-0432.CCR-23-0362
Published: 01 September 2023
View articletitled, Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial
Open the PDF for Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial

Open Access
Peter A. Fasching, Christopher Szeto, Carsten Denkert, Stephen Benz, Karsten Weber, Patricia Spilman, Jan Budczies, Andreas Schneeweiss, Elmar Stickeler, Sabine Schmatloch, Christian Jackisch, Thomas Karn, Hans Peter Sinn, Mathias Warm, Marion van Mackelenbergh, Shahrooz Rabizadeh, Christian Schem, Ernst Heinmöller, Volkmar Mueller, Frederik Marmé, Patrick Soon-Shiong, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2456–2465.
https://doi.org/10.1158/1078-0432.CCR-22-2213
Published: 05 July 2023
View articletitled, Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Open the PDF for Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Open Access
Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1569–1581.
https://doi.org/10.1158/1078-0432.CCR-22-1989
Published: 14 April 2023
View articletitled, Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Open the PDF for Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Available to Purchase
Bruno V. Sinn, Sibylle Loibl, Claus A. Hanusch, Dirk-Michael Zahm, Hans-Peter Sinn, Michael Untch, Karsten Weber, Thomas Karn, Clemens Becker, Frederik Marmé, Wolfgang D. Schmitt, Volkmar Müller, Christian Schem, Denise Treue, Elmar Stickeler, Frederik Klauschen, Nicole Burchardi, Jenny Furlanetto, Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2584–2591.
https://doi.org/10.1158/1078-0432.CCR-20-3113
Published: 01 May 2021
View articletitled, Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Open the PDF for Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Available to Purchase
Thomas Karn, Tobias Meissner, Karsten E. Weber, Christine Solbach, Carsten Denkert, Knut Engels, Peter A. Fasching, Bruno V. Sinn, Iris Schrader, Jan Budczies, Frederik Marmé, Volkmar Müller, Uwe Holtrich, Bernd Gerber, Christian Schem, Brandon M. Young, Claus Hanusch, Elmar Stickeler, Jens Huober, Marion van Mackelenbergh, Brian Leyland-Jones, Tanja Fehm, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1896–1904.
https://doi.org/10.1158/1078-0432.CCR-19-1954
Published: 15 April 2020
View articletitled, A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Open the PDF for A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial in another window
Includes: Supplementary data
Journal Articles

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial

Free
Sibylle Loibl, Denise Treue, Jan Budczies, Karsten Weber, Albrecht Stenzinger, Wolfgang D. Schmitt, Wilko Weichert, Paul Jank, Jenny Furlanetto, Frederick Klauschen, Thomas Karn, Nicole Pfarr, Gunter von Minckwitz, Markus Möbs, Christian Jackisch, Christine Sers, Andreas Schneeweiss, Peter A. Fasching, Christian Schem, Michael Hummel, Marion van Mackelenbergh, Valentina Nekljudova, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3986–3995.
https://doi.org/10.1158/1078-0432.CCR-18-3258
Published: 01 July 2019
View articletitled, Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Open the PDF for Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial in another window
Includes: Supplementary data
Journal Articles

Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial

Free
Sabine Riethdorf, Volkmar Müller, Sibylle Loibl, Valentina Nekljudova, Karsten Weber, Jens Huober, Tanja Fehm, Iris Schrader, Jörn Hilfrich, Frank Holms, Hans Tesch, Christian Schem, Gunter von Minckwitz, Michael Untch, Klaus Pantel
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5384–5393.
https://doi.org/10.1158/1078-0432.CCR-17-0255
Published: 14 September 2017
View articletitled, Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Open the PDF for Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial in another window
Includes: Supplementary data
Journal Articles

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

Free
Barbara Ingold Heppner, Michael Untch, Carsten Denkert, Berit M. Pfitzner, Bianca Lederer, Wolfgang Schmitt, Holger Eidtmann, Peter A. Fasching, Hans Tesch, Christine Solbach, Mahdi Rezai, Dirk M. Zahm, Frank Holms, Manfred Glados, Petra Krabisch, Esther Heck, Angelika Ober, Petra Lorenz, Kurt Diebold, Jörg-Olaf Habeck, Sibylle Loibl
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5747–5754.
https://doi.org/10.1158/1078-0432.CCR-15-2338
Published: 30 November 2016
View articletitled, Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Open the PDF for Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

Free
Sibylle Loibl, Silvia Darb-Esfahani, Jens Huober, Alexander Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gunter von Minckwitz, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (11): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-15-0965
Published: 31 May 2016
View articletitled, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)

Free
Claus Hanusch, Andreas Schneeweiss, Sibylle Loibl, Michael Untch, Stefan Paepke, Sherko Kümmel, Christian Jackisch, Jens Huober, Jörn Hilfrich, Bernd Gerber, Holger Eidtmann, Carsten Denkert, Serban Costa, Jens Uwe Blohmer, Knut Engels, Nicole Burchardi, Gunter von Minckwitz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2924–2931.
https://doi.org/10.1158/1078-0432.CCR-14-2774
Published: 30 June 2015
View articletitled, Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)
Open the PDF for Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) in another window